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The metabolism of high intakes of tryptophan, nicotinamide and 
nicotinic acid in the rat 
BY GWYN M. McCREANOR* A N D  DAVID A. BENDER 
Courtauld Institute of Biochemistry, The Middlesex Hospital 
Medical School. London WI P 7PN 
(Received 24 February 1986 - Accepted 15 July 1986) 
1. The metabolic fate of high dietary intakes of nicotinamide, nicotinic acid and tryptophan, and of acute doses 
of nicotinamide and nicotinic acid, has been studied in the rat. A new high-pressure liquid chromatography method 
for measurement of the principal urinary metabolites of niacin is described. 
2. Administration to rats of a single oral dose of nicotinamide or nicotinic acid (up to 100 mg/kg body-weight), 
or maintenance for 3 weeks on diets providing 150 mg nicotinamide or nicotinic acid/kg diet, resulted in only 
a small increase in the liver content of nicotinamide nucleotide coenzymes (NAD and NADP). The quantitative 
metabolism of nicotinamide and nicotinic acid differed, suggesting that intestinal bacterial deamidation is not the 
major fate of nicotinamide. 
3.  A high dietary intake of tryptophan (5.9 g/kg diet) led to a considerable increase in liver NAD(P) and also 
in urinary excretion of niacin metabolites. The results suggest that, as indicated by enzyme kinetic studies (Bender 
et al. 1982), the utilization of nicotinamide and nicotinic acid for nucleotide synthesis is limited, while there is 
little or no limitation of NAD(P) synthesis from the tryptophan metabolite quinolinic acid. 
The established physiological function of niacin is as a precursor of the nicotinamide 
nucleotide coenzymes, NAD and NADP. The conventional view is that tryptophan can 
‘substitute’ for niacin when the dietary intake of the vitamin is inadequate, since the amino 
acid can give rise to the nicotinamide nucleotides by way of quinolinic acid, an intermediate 
in the oxidative pathway of tryptophan metabolism (see Fig. 1). 
There are several clinical conditions in which pellagra results from disturbed tryptophan 
metabolism despite an apparently adequate intake of niacin. Examples include Hartnup 
disease (Baron et al. 1956), carcinoid syndrome (Castiello & Lynch, 1972; Lehman, 1972; 
Swain et al. 1976), the treatment of tuberculosis with isoniazid (Biehl & Vilter, 1954; 
Harrison & Feiwel, 1956) and a recently described hereditary pellagra-like condition which 
did not respond to the administration of nicotinamide (Salih et al. 1985). All these findings 
suggest that under normal conditions tryptophan may be more important as a precursor 
of the nucleotides than is preformed dietary niacin. A recent re-examination of the diets 
of American pellagrins during the 1930s and 1940s by Carpenter & Lewin (1985) confirms 
this view. They calculated that the average intake of available niacin equivalents was 
apparently adequate in most cases of confirmed pellagra, and concluded that ‘the pellagra 
epidemic in the USA in the early 1900s has not yet been explained satisfactorily’. A previous 
study from this laboratory (Bender et al. 1982) suggested, largely on the basis of enzyme 
kinetic studies, that the utilization of nicotinamide and nicotinic acid for nucleotide 
synthesis was strictly limited, while there was little or no limitation of NAD(P) synthesis 
from the tryptophan metabolite quinolinic acid. 
Very high intakes of niacin, many times larger than the conventionally accepted vitamin 
levels, are used clinically : nicotinic acid as a hypolipidaemic-hypocholesterolaemic agent 
(Parsons, 1961 a), and nicotinamide in the treatment of schizophrenia (Osmond & Hoffer, 
1962; Hoffer, 1971) and other psychiatric disorders (Blom et al. 1985). It is often assumed 
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Fig. 1. Pathways of nicotinamide nucleotide coenzyme synthesis and catabolism. (U) ,  Picolinate 
carboxylase (aminocarboxymuconate-semialdehyde decarboxylase, EC 4.1 . 1 .45); (b), quinolinate phos- 
phoribosyltransferase (nicotinate nucleotide pyrophosphorylase (carboxylating), EC 2.4.2.19); (c), 
nicotinate phosphoribosyltransferase (EC 2.4.2.1 1); (d), nicotinamide deamidase (nicotinamidase, 
EC 3.5.1.19); (e), nicotinamide phosphoribosyltransferase (EC 2.4.2.12); (J) NAD+ nucleosidase 
(EC 3.2.2.5) and poly-(ADP-ribose) synthetase (NAD+ ADP-ribosyltransferase, EC 2.4.2.30). 
that like the other water-soluble vitamins, niacin is not toxic, since it is readily metabolized 
and excreted. However, in addition to the acute toxicity of single large doses of nicotinic 
acid (Bartlett et al. 1982), there is evidence of hepatotoxicity associated with the intake of 
relatively large amounts of both nicotinic acid (Parsons, 1961 a, b ;  Baggenstoss er al. 1967) 
and nicotinamide (Winter & Boyer, 1973; Kang-Lee et al. 1983). 
The present study was undertaken in order to investigate further the relative importance 
of tryptophan and preformed dietary nicotinic acid and nicotinamide as precursors of the 
nicotinamide nucleotide coenzymes, and to investigate the metabolic fate of large amounts 
of niacin. 
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METHODS 
Animals and diets 
Male Wistar rats bred in the Courtauld Institute of Biochemistry were used. For the acute 
studies they were maintained on standard animal house diet (diet 86; A. Dixon & Sons, 
Ware, Herts) for 3 weeks after weaning. According to information provided by the 
manufacturers, this diet provided 2.4 g tryptophan and 73 mg nicotinic acid/kg. The rats 
received a single dose of 1, 10 or 100 mg nicotinic acid or nicotinamide/kg body-weight, 
dissolved in saline (0.15 M-sodium chloride; 0.5 ml per animal), by oral intubation. Control 
animals received 0.5 ml saline alone. They were then housed in individual stainless steel 
metabolism cages (Acme Metal CO, Chicago, Ill) for 24 h, to permit collection of urine. 
During this period they were allowed free access to water, but were deprived of food. Each 
24 h collection of urine was diluted to 20 ml with distilled water, then frozen and stored 
at - 20" until required. 
For the diet studies, animals were weaned on to the experimental diets 21 d after birth, 
and were maintained on them for 3 weeks, after which they were housed in metabolism 
cages for 24 h for collection of urine, as described previously. They were allowed ad lib. 
access to food and water; the food intakes shown in Table 3 (p. 582) were determined during 
this period. The diets used were prepared as described previously (Bender et al. 1982), and 
were a modification of the maize-gelatine-sucrose diet described by Carter et al. (1977). 
Six different diets were used, as shown in Table 3. Two diets provided no preformed niacin 
apart from that present in the maize meal, with an adequate (1.9 g/kg) or more than 
adequate (5.9 g/kg) amount of tryptophan. The other four diets provided a minimum 
amount of tryptophan, determined previously to be adequate to permit limited growth of 
weanling rats (Magboul & Bender, 1983), with either nicotinic acid or nicotinamide added 
at 15 mg/kg ((US) National Research Council (1962) recommended amount for the rat) 
or 150 mg/kg. 
Analytical methods 
The rats were killed by cervical dislocation and a portion of the liver (about 1 g) was rapidly 
dissected out, frozen in liquid nitrogen and used for measurement of total nicotinamide 
nucleotides (NAD(P)+ and NAD(P)H), by the fluorimetric method described previously 
(Bender et al. 1982); a modification of the methods described by Kaplan et al. (1951) and 
Lowry et al. (1961). 
W-Methyl nicotinamide was measured by the small-scale modification of the alkali- 
ketone fluorimetric method of Carpenter & Kodicek (1 950) described previously (Bender, 
1980). 
Methyl-2-pyridone-5-carboxamide was synthesized by the method of Holman & Wiegand 
(1948); other niacin metabolites were purchased from Sigma (London) Chemical CO Ltd, 
Poole, Dorset. 
High-pressure liquid chromatography (HPLC) determ~na~~on of urinary niacin metabolites 
The samples were desalted by the addition of 15 ml acetone to 5 ml diluted urine. After 
standing at room temperature for 30 min, precipitated salts were removed by centrifugation 
at 2000 g for 20 min, and the acetone was removed by extraction twice with 5 ml 
chloroform. Of the resultant aqueous phase, 2 ml was mixed with 0.2 ml2.5 M-ammonium 
hydroxide, and was loaded on to a column of Dowex 1 C1- ion-exchange resin. The columns 
of resin were prepared by pouring an aqueous slurry of resin into a Pasteur pipette plugged 
at the constriction with glass wool, and each contained 300 mg dry weight of resin. The 
columns were washed with 10 m12 M-hydrochloric acid, followed by 10 ml distilled water, 
before the application of the sample. 
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Table 1. Retention times of tryptophan and niacin metabolites on high pressure liquid 
chromatography (HPLC) 
(HPLC was performed using a 250 mm x 5 mm column of Partisil 10-SCX cation-exchange resin, 
eluted isocratically at 1.5 ml/min with 0.05 M-sodium phosphate buffer, pH 1.7, containing methanol 
(1 00 ml/l)) 
Compound 
Retention time Fraction from 
(min) Dowex 1 column 
iso-Nicotinic acid 
Nicotinamide N-oxide 
Methyl-2-pyridone-5-carboxamide 
Picolinic acid 
Nicotinic acid 
Nicotinuric acid 
Unidentified peak (tentatively assumed to be 
Nicotinamide 
W-Methyl nicotinamide 
methyl-4-pyridone-2-carboxamide) 
4.3 
44 
5.2 
5.3 
5 .8  
7.7 
8.0 
11.7 
33 
Acidic 
Neutral 
Neutral 
Acidic 
Acidic 
Acidic 
Neutral 
Neutral 
Neutral 
The initial eluate from the column and that from washing with 8 ml water were collected; 
neutral compounds (nicotinamide, nicotinamide N-oxide, NI-methyl nicotinamide and 
methyl-2-pyridone-5-carboxamide) were in this fraction. Acidic compounds (nicotinic and 
nicotinuric acids) were then eluted with 4ml  1 M-HCl. The eluates were evaporated to 
dryness in a vortex evaporator under reduced pressure at 60", and were then redissolved 
in 0.2 ml 0.05 M-sodium phosphate buffer, pH 1.7, containing methanol (100 ml/l). In 
order to determine whether any of the unidentified peaks that were detected by HPLC were 
due to glucuronide or sulphate conjugates, samples of the urine extract prepared for HPLC 
were incubated with 1000 units of a preparation of /3-glucuronidase (EC 3.2.1 . 3  1) from 
Helix pomatia (Sigma (London) Chemical CO Ltd), containing 50 units of sulphatase 
activity, at pH 5.0 and 30" for 60 min. 
Preliminary studies showed that the initial separation into acidic and neutral fractions 
before HPLC was necessary because picolinic acid, a metabolite of tryptophan which elutes 
in the acidic fraction, had the same retention time on HPLC (5.3 min) as methyl- 
2-pyridone-5-carboxamide (5.2 min), which elutes in the neutral fraction. Similarly, iso- 
nicotinic acid, which was added to samples as an internal standard, overlapped with 
nicotinamide N-oxide unless they were first separated by ion-exchange chromatography 
(see Tabie 1). 
HPLC was carried out using a Partisil 10-SCX cation-exchange column (250 mm x 5 mm) 
with a protective precolumn (50 mm x 5 mm) of Spherisorb ODS reverse-phase medium. 
The column was equilibrated with the same 0.05 M-sodium phosphate buffer (pH 1.7 
containing methanol (100 ml/l)) as was used to redissolve the samples after column 
chromatography. Samples were injected on to the column using a Rheodyne syringe-loading 
injection valve with a 20 ,ul loop, and a single pump was used to elute materials isocratically 
at a flow rate of 1.5 ml/min. Compounds in the eluate were detected by absorption at 
265 nm, using an 8 pl flow cell in a Cecil CE-272 spectrophotometer attached to a Hewlett 
Packard 3390A recording integrator. 
R E S U L T S  
Preliminary studies showed good recovery of authentic standards of niacin metabolites 
through the HPLC procedure, with linearity over the range of 0.01 5-1.0 mM concentrations 
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Niacin metabolism in the rat 583 
of all the metabolites measured. The retention times of the standards are shown in Table 
1 .  Quinolinic acid could not be separated from the peak associated with the solvent front 
by this method. The limit of reliable detection was 1 pmol injected onto the column for 
nicotinamide and 0-5 pmol for the other metabolites studied. NI-Methyl nicotinamide was 
not routinely measured by HPLC because it gave a broad diffuse peak, with a retention 
time of 33 min. 
There was one major peak of U.V. absorbing material in rat urine that increased with 
increasing intake or dose of niacin; it was in the neutral fraction and had a retention time 
of 8.0 min. There were also a number of minor peaks. None of these has yet been identified, 
but preliminary studies suggest that none is a glucuronide or sulphate conjugate, since they 
were unaffected by incubation with a preparation of P-glucuronidase and sulphatase. It is 
likely that the major peak was methyl-4-pyridone-3-carboxamide, but no authentic sample 
of this was available to permit identification and quantification. 
As observed previously (Bender et al. 1982), the animals fed on the diets providing 
tryptophan as the only precursor of nicotinamide nucleotides grew faster than those fed 
on low-tryptophan diets providing an adequate or more than adequate amount of 
nicotinamide or nicotinic acid, suggesting some degree of growth restriction by ,the low 
amount of tryptophan provided by these diets. 
The liver content of NAD(P) and urinary excretion of niacin metabolites in animals 
receiving a single dose of nicotinic acid or nicotinamide are shown in Table 2 and, for 
animals receiving the six different diets described previously, in Table 3. 
DISCUSSION 
The acute dose of 10 mg niacin/kg body-weight is approximately equal to the daily intake 
of animals fed on diets providing 150 mg niacin/kg diet. However, this acute dose was 
superimposed on the relatively high amounts of nicotinic acid (73 mg/kg) and tryptophan 
(2.4 g/kg) provided by the stock diet. It is therefore difficult to make direct comparisons 
between the results shown in Tables 2 and 3. Furthermore, it is to be expected that the 
metabolism of a single acute oral dose of niacin will differ from that of the same amount 
taken over the 4-6 h feeding period of the rat. 
Neither nicotinic acid nor nicotinamide was excreted unchanged in substantial amounts 
in the diet study or after a single dose, except at the highest doses given (100 mg/kg 
body-weight). This is in agreement with the results of Corr & May (1975), who showed that 
nicotinic acid and nicotinamide are both actively resorbed from the glomerular filtrate, and 
will only be excreted in the urine when the concentration in the bloodstream is so high that 
the renal transport system is saturated. 
In response to a single dose of nicotinic acid or a single high dose of nicotinamide 
(100 mg/kg body-weight), there was a significant increase in the concentration of NAD(P) 
in the liver. Previous studies (Bender er al. 1982) have shown that nicotinate phospho- 
ribosyltransferase (EC 2.4.2.1 1) is not saturated at physiological concentrations of 
nicotinic acid, and therefore some increase in nucleotide synthesis might be expected with 
increasing availability of the substrate. However, nicotinamide phosphoribosyltransferase 
(EC 2.4.2.12) is saturated at physiological concentrations of its substrate. It is therefore 
unlikely that the increased concentration of nucleotides in the liver after a single high dose 
of nicotinamide is due to increased synthesis. Rather it is probable that it is the result of 
decreased catabolism; both nicotinamide and W-methyl nicotinamide, but not nicotinic 
acid, inhibit poly-(ADP-ribose) synthetase (NAD+ ADP-ribosyltransferase, EC 2.4.2.30), 
one of the two enzymes involved in the catabolism of NAD (Berger et al. 1978; Levi et 
al. 1978; Purnell & Whish, 1980). 
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The excretion of N1-methyl nicotinamide and methyl-2-pyridone-5-carboxamide increa- 
sed with increasing doses of nicotinamide, and at  high doses there was also an increase in 
the excretion of nicotinamide N-oxide. At high doses of nicotinic acid there was also a small 
increase in the excretion of N1-methyl nicotinamide and methyl-2-pyridone-5-carboxamide. 
While this might suggest some increased synthesis and catabolism of NAD, it might also 
reflect amidation of nicotinic acid to nicotinamide; reversal of the reaction of nicotinamide 
deamidase (nicotinamidase, EC 3.5.1 .19). 
Nicotinuric acid excretion was increased not only after the administration of its precursor, 
nicotinic acid, but also, to a lesser extent, after the administration of 100 mg nicotin- 
amide/kg body-weight. The kinetic properties of rat liver nicotinamide deamidase are 
such that this enzyme is saturated at the normal steady-state concentration of nicotinamide 
in liver (Bender et al. 1982). Therefore it is not likely that there will be any additional acti- 
vity at very high concentrations of nicotinamide, unless there is an isoenzyme of the 
deamidase with a very high Michaelis-Menten constant which has not been reported to 
date. However, a number of intestinal micro-organisms have nicotinamide deamidase acti- 
vity (Gadd & Johnson, 1974; Johnson & Gadd, 1974) and it is possible that following a 
large oral dose of nicotinamide, bacterial deamidation in the intestinal lumen is an impor- 
tant route of metabolism, leading to absorption and subsequent metabolism of nicotinic 
acid. Indeed, Johnson & Gadd (1974) have suggested that intestinal deamidation is the 
normal major fate of dietary nicotinamide. The present results do not support this sugges- 
tion, since the urinary metabolites of nicotinic acid and nicotinamide were quantitatively 
different in both the acute study (Table 2 )  and the diet study (Table 3). 
Osmond & Hoffer (1962) suggested a possible metabolic mechanism to explain the 
claimed anti-schizophrenic action of high doses of nicotinamide (up to 20 g/d for an adult; 
Hoffer et al. 1957; Hoffer, 1971), although the efficacy of such so-called ‘mega-vitamin 
therapy’ has been challenged by a number of controlled trials, reviewed by Ban (1974), 
which have failed to demonstrate any significant anti-schizophrenia action of nicotinamide. 
One of the theories of the biochemical basis of schizophrenia is that there is abnormal 
methylation of a neurotransmitter or metabolite to produce an endogenous psychotogen, 
chemically akin to some of the hallucinogenic drugs (Pollin et al. 1961). Osmond & Hoffer 
(1962) suggested that nicotinamide might reduce this abnormal methylation by acting as 
a ‘sink’ for methyl groups and depleting tissue reserves of single carbon units. Kang-Lee 
et al. (1983) showed some reduction in the total choline concentration in the plasma and 
liver of rats fed on a choline-free diet, as the intake of nicotinamide was increased from 
60 to 600 mg/kg body-weight per d. While the majority of the niacin metabolites recovered 
in the present study were indeed methylated, the proportion of the dose of nicotinamide 
recovered as N7-methyl nicotinamide and methyl-2-pyridone-5-carboxamide decreased as 
the intake increased. It is therefore considered unlikely that high doses of nicotinamide 
would result in any metabolically important depletion of tissue methyl group donors. This 
is confirmed by preliminary studies of the effects of feeding rats on choline- and 
methionine-deficient diets. Depletion of tissue pools of methyl donors would be expected 
to reduce the ratio, phosphatidylcholine : phosphatidylethanolamine in membrane phos- 
pholipids. However, there was no change in the ratio, phosphatidylcholine: phosphatidyl- 
ethanolamine in response to a prolonged, very high intake of nicotinamide (1 500 mg/kg 
diet for 7 weeks) (Bender et al. 1987). 
The results of the diet study provide some insight into the relative importance of 
tryptophan and preformed dietary niacin as precursors of the nicotinamide nucleotide 
coenzymes. Assuming that 30 mg dietary tryptophan is equivalent to 1 mg niacin, the usual 
equivalence for the rat (Krehl et al. 1946; Hankes et al. 1948), the high-tryptophan diet 
provided the equivalent of 196 mg niacin/kg, almost the same as the high-niacin diets 4 
Niacin metabolism in the rat 58 5 
and 6 (150 mg/kg). However, comparing the results in Table 3 for diets 1 and 2, it can be 
seen that an almost threefold increase in tryptophan intake resulted in a 2.6-fold increase 
in liver NAD(P), whereas a tenfold increase in dietary nicotinamide (diets 3 and 4) or 
nicotinic acid (diets 5 and 6) resulted in only a 50% increase in liver nucleotides. There was 
also a greater increase in the urinary excretion of three niacin metabolites, iV-methyl 
nicotinamide, methyl-2-pyridone-5-carboxamide and nicotinuric acid in response to a 
threefold increase in tryptophan intake than to a tenfold increase in niacin intake. These 
results support the suggestion made previously (Bender et al. 1982) that the utilization of 
nicotinic acid and nicotinamide is limited by the phosphoribosyltransferases involved (see 
Fig. l), which are more or less saturated at the normal steady-state concentrations of 
nicotinamide and nicotinic acid in the liver, while there is no such limitation of the 
incorporation into nucleotides of quinolinic acid arising from tryptophan metabolism. The 
considerable increase in urinary niacin metabolites in animals fed on the high-tryptophan 
diet suggests that control of tissue concentrations of NAD(P) may be achieved largely by 
altering the rate of catabolism, as indicated by studies of the effects of hypoxia and 
hyperoxia (McCreanor & Bender, 1983). 
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